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Abstract: Approximately 20% of children with hepatoblastoma (HB) have metastatic disease at
diagnosis, most frequently in the lungs. In children with HB, lung metastatic disease is associated
with poorer prognosis. Its treatment has been approached with a variety of methods that integrate
chemotherapy and surgical resection. The timing and feasibility of complete extirpation of lung
metastases, by chemotherapy and/or metastasectomy, is crucial for the surgical treatment of the
primary liver tumor, which can vary from major hepatic resections to liver transplantation (LT).
In children with unresectable HB, which can be surgically treated only by LT, the persistence of
unresectable metastases after neoadjuvant chemotherapy excludes the possibility of recurring to LT
with consequent negative impact on patients’ outcomes. Due to limited evidence and experience,
there is no consensus amongst oncologists and surgeons across institutions regarding the surgical
treatment for HB with synchronous metastatic lung disease. This narrative review aimed to update
the current management of pulmonary metastasis in children with HB and to define its role in the
decision-making strategy for the surgical approach to primary liver tumours.
Keywords: lung metastases in hepatoblastoma; high-risk hepatoblastoma; liver resection; liver
transplantation; metastasectomy
1. Introduction
Hepatoblastoma (HB) is the most common paediatric primary liver tumour, generally detected
within the third year of life [1], with an increasing annual incidence of 1.5 cases per million [2].
According to different protocols, the overall survival in HB has dramatically increased in the last
years mainly owing to advances in chemotherapy (CHT), reaching an overall 5-year survival of
70–80% [3]. The current strategy of HB treatment is based on different approaches including delayed
tumor resection after pre-operative chemotherapy (CHT) or, in selected cases, upfront resection with
or without post-operative CHT.
HB can metastasize in several organs, including the adrenal gland, colon, diaphragm, kidney,
and lungs. It is estimated that around one fifth of children with HB present pulmonary metastasis at
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diagnosis [4]. This phenomenon is one of the poorest prognostic factors in HB. In the presence of lung
metastasis, the 5-year event-free survival (EFS) is approximately 21–28%, while the overall survival
ranges from 25 to 50% [5,6].
Lung metastasis are generally defined as a single nodule more than 10 mm or several nodules
with at least one more than 5 mm. Computed tomography (CT) is the gold standard in the diagnosis of
lung metastasis, and it is usually performed as a routine exam during the diagnostic assessment [7].
However, this technique still faces some limitations in paediatric solid tumours despite the remarkable
technologic improvements. Although the CT scan is highly sensitive, it lacks specificity for differential
diagnosis between malignant and benign lung nodules. Furthermore, its resolution is not always able
to detect the smallest nodules [7].
In the last decades, cisplatin-based CHT has achieved excellent results in children with HB [1,4,8,9].
Cisplatin is either used alone or combined with doxorubicin, 5–fluorouracil and/or vincristine for
advanced HB. Although the optimal schedule and doses for a chemotherapeutic regimen are not yet
defined, worldwide several HB therapeutic protocols have been adopted and all international studies
demonstrated that CHT is of the utmost importance to treat HB with synchronous lung metastases.
Indeed, CHT achieves up to 80% metastasis resolution [6]. When lung metastasis are not resolved by
CHT or relapse occurs, surgical metastasectomy is an effective alternative option [6].
The timing and feasibility of complete extirpation of lung metastasis, by medical and/or surgical
treatment, is crucial for the surgical approach to the primary liver tumor, which can vary from major
hepatic resections to liver transplantation (LT). In children with unresectable HB, which can be surgically
treated only by LT, the persistence of unresectable metastases after neoadjuvant chemotherapy exclude
the possibility of recurring to LT with consequent negative impact on patients’ outcomes. Due to
limited evidence and experience, there is no consensus amongst oncologists and surgeons across
institutions regarding the surgical treatment for HB with synchronous metastatic lung disease. Thus,
the present study aimed to review and describe the outcomes of HB with synchronous lung metastasis
in consideration of possible surgical approaches, for both primary and secondary tumours, to the best
of the available literature.
2. Material and Methods
2.1. Search Strategy
A systematic search was performed to identify relevant studies focused on the therapeutic
management and outcomes of children affected by HB with lung metastases at diagnosis. The search
strategy complied with the Preferred Reporting Items for Systemic Reviews and Meta-Analysis
(PRISMA) guidelines [10]. A search of the electronic databases MEDLINE-PubMed, Ovid Medline, and
EMBASE was conducted using the following search terms: hepatoblastoma, liver transplantation, liver
resection, metastasis, high-risk, advanced. Studies published before 21 May 2019 were considered.
2.2. Screening Process
The present qualitative systematic review included a priori search criteria of journal articles
amongst children (<18 years) affected by HB. Records of children affected by HB with lung metastasis
present at diagnosis that detailed the outcomes of the pulmonary metastasis and the surgical
management of the primary liver tumour were included. Studies were limited to the English language.
Exclusion criteria were studies that lacked surgical details, did not report outcomes of lung
metastasis, and described HB metastasis other than pulmonary. Additionally, review articles,
non-clinical studies, guidelines, case reports, expert opinions, letters to the editor, and conference
summaries were excluded. All studies that originated from the same centre were considered and
analyzed, and the possible overlap of clinical cases reported across the studies was evaluated.
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2.3. Study Selection and Data Extraction
A total of 564 articles were observed. Two reviewers (RA and CG) independently screened the
identified studies and their data was extracted. In case of disagreement, the paper was discussed by all
the authors. After the systematic screening, 56 studies were identified for systematic review analysis
(Figure 1). Given the paucity of patients identified within the selection criteria in each selected study,
the results are reported as a narrative review.
Data extracted from each study included (where available): year of publication, inclusion criteria,
exclusion criteria, number of participants, and the data-relevant outcome variables explained above.
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3. Hepatoblastoma (HB) Risk Stratificatio
In the last two decades, HB risk tra ification has been studied by sev ral international groups who
actively ooperated and contributed to improve outcomes in patients affected by HB: the Children’s
Oncology Group (COG), the International Childhood Liver Tumour St ategy G oup (SIOPEL), the
Children’s Cancer Group (C G) and the Pediatric Oncology Group (POG), the German Society for
Paediatric Oncology and Haematology (GPO ) and the Japanese Study Group for Pediatric Liver
Tumors (JPLT).
Worldwide, the pre-treatment extent of disease (PRETEXT) system is the most-used staging tool for
HB. It determines the liver sectors affected by HB before any treatment commences [11]. Each patient
diagnosed with HB is assigned to a PRETEXT group (I, II, III, or IV) based on the number of contiguous
uninvolved sections of the liver. Moreover, annotation factors are included in the PRETEXT staging
system, defining the involvement of major vascular structures of the liver and extrahepatic sites.
Annotation factors comprise “V”: involvement of the retrohepatic inferior vena cava or involvement of
all three major hepatic veins; “P”: involvement of the portal vein; “E”: extrahepatic involvement of
contiguous structures; “M”: distant metastatic disease; “F”: multifocal liver tumours; “R”: tumour
rupture [12,13]. Multiple trials have confirmed that the PRETEXT stage is a powerful predictor of
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patients’ survival, and drives the medical and surgical treatment of HB. Therefore, the PRETEXT and
the annotation factors have been adopted in the current Pediatric Hepatic International Malignancy
Therapeutic Trial (PHITT), which is the largest ongoing single clinical trial undertaken in children with
HB as collaboration among the SIOPEL, COG, and JPLT study groups [12,14].
The same classification criteria are used to evaluate the post-treatment extent of disease (POSTTEXT)
of HB after CHT. While the PRETEXT staging is strictly related to the prognosis, the POSTTEXT is the
most important factor in planning the surgical resection [11–13].
In 2013, the Children’s Hepatic Tumors International Collaboration (CHIC) created a shared
international database to provide novel prognostic factors with the overarching goal of developing a
common risk stratification scheme for HB [3]. The CHIC database includes data from 1605 children
treated in eight multicentre HB trials based on cisplatin–CHT and complete surgical resection over 25
years. The CHIC study analyzed the PRETEXT staging by centrally reviewing the tumour imaging (CT
or magnetic resonance) [3]. The initial CHIC univariate analysis identified several factors associated
with poor outcomes in children with HB: PRETEXT IV, macrovascular hepatic or portal involvement,
contiguous extrahepatic disease, multifocality of the primary tumor, metastatic disease, tumor rupture,
low alpha–fetoprotein (AFP) levels (<100 ng/mL) or high AFP levels (>1 million ng/mL) at diagnosis,
age (≥8 years), low birth weight (<1500 gr), prematurity, and comorbidities (Beckwith-Wiedemann
syndrome) [3].
Based on these specific prognostic factors, the CHIC group recently developed a new HB
risk-stratified staging system, named CHIC–HB Stratification (CHIC–HS), according to five group
classifications which showed a 5-year EFS of 86% for PRETEXT I/II, 82% for PRETEXT III, 60% for
PRETEXT IV, 42% for metastatic disease, and 35% for AFP concentration ≤ 100 ng/mL at diagnosis [2].
Age at diagnosis, AFP levels, and PRETEXT stage remained statistically significant prognostic factors
for all sub-groups [2]. Based on those variables, each patient is assigned to a risk group, which defines
his prognosis as very low/low risk (EFS ≥ 89%), intermediate risk (EFS of 50–88%) or high risk (EFS
< 50%) [2]. Currently, the CHIC–HB stratification is a useful tool to define the prognosis of children
diagnosed with HB, and it is being currently validated in the PHITT trial [14]. Moreover, in future
prospective the new CHIC risk stratification might potentially also direct the therapeutic management
of HB.
In the CHIC–HS, the presence of metastatic disease at diagnosis is defined as “high-risk”,
independent of the PRETEXT staging, and has been found in 20% of the study population. For the
sub-group of children affected by metastatic HB, the AFP level was identified as the most significant
prognostic factor: an AFP level of 100–1000 ng/mL at diagnosis was related to a 5-year EFS of 18%, while
children with AFP > 1000 ng/mL had a 5-year EFS of 47% (p < 0.0001) [2]. The second most significant
prognostic factor for metastatic HB was age at presentation, with worse prognosis for children aged
≥8 years. Lastly, PRETEXT III–IV and the presence of one or more of PRETEXT annotation factors
(such as involvement of IVC, portal vein, extrahepatic contiguous tumour extension, multifocal liver
lesions, or tumor rupture at diagnosis) also were associated with inferior outcomes [2,3].
4. Hepatoblastoma (HB) Treatment Algorithms
HB treatment requires a multi-modal approach of CHT combined with surgery, and it strictly
relies on the PRETEXT and POSTTEXT staging of the tumour, its biology, presence of metastases, and
response to neoadjuvant CHT (primary tumour mass reduction, decrease in AFP levels). The goal
of HB therapy is radical extirpation of the tumor. There have been substantial improvements in HB
treatment in recent years: from a few treatment options, there is now a detailed tumor risk-management
plan that includes CHT and several surgical approaches [2,4,15].
According to the principal protocols [5,6,15–20], at diagnosis the assessment of HB includes:
(1) total body CT scan to define the PRETEXT stage with the annotation factors (V,P,E,F,R); (2) tumor
biopsy in order to determinate the HB histological subtype (well-differentiated fetal HB, embryonal
HB, small cell undifferentiated HB), which have been associated to different prognosis [13]; and
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(3) AFP blood levels. Based on those results, each trial followed a treatment algorithm, which may
differ for the role of surgical resection at diagnosis and CHT regimens, and have been extensively
described [6,15–20]. As first line-therapy, children may be treated by upfront surgery or by neoadjuvant
CHT with subsequent surgical resection of the primary tumor. In COG guidelines, upfront primary
tumor resection at diagnosis is recommended only in selected patients with PRETEXT I and II tumors
(“very low” risk) with absence of macrovascular involvement defined as more than 1 cm radiographic
free tumor margin from the middle hepatic vein, the retrohepatic inferior vena cava, and the portal
bifurcation [2,5].
For PRETEXT III–IV or HB with synchronous metastatic disease (“high-risk”), all trials recommend
neoadjuvant cisplatin-based CHT before considering any surgical resection. After 2–4 cycles of CHT,
tumours should be re-imaged in order to outline the POSTTEXT stage with definition of surgical
resectability of the primary liver tumor, the response of pulmonary metastases (if present at diagnosis)
and whether further CHT is needed [13]. At this time point, focus on extra-hepatic tumor extension is
pivotal in orienting the subsequent strategies (Figure 2).
Currently, the PHITT [14], which is a randomized interventional study based on the risk-adapted
therapeutic approach, is exploring: (a) the reduction of chemotherapic treatment for low risk HB
patients (aiming to maintain their excellent event free survival, but also to decrease acute and long-term
toxicity); (b) intensification of therapy with the use of novel agents in the high-risk group; and
(c) comparison of three different regimens in intermediate risk HB. A key strand of the PHITT trial is
the evaluation of the biology of HB, using the identification/validation of novel and already reported
prognostic biomarkers as well as toxicity biomarkers. In addition, the PHITT aims also to evaluate a
surgical planning instrument for an impact on the decision-making process in POSTTEXT III and IV
HB. Therefore, in the next future the PHITT results will provide practical tools to achieve personalized
treatment in children with HB, not only for the CHT regimen but also for the surgical approach.
As the objective of our review, in the following paragraphs we summarize the management and
outcomes of children affected by HB with synchronous lung metastasis reported in literature, focusing
on the surgical treatment of the primary liver tumor (surgical resection, LT, non-surgical treatments)
and lung metastases.
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5. Hepatoblastoma (HB) with Synchronous Lung Metastasis
Around 20% of children with HB have synchronous lung metastasis at diagnosis and these patients
are burdened by an overall 25–50% lower survival range compared to those without [6]. As reported
by the principal HB trials (Table 1), the outcomes of children with HB and synchronous lung metastases
have significantly improved in the last decades due to the intensification of CHT regimens, which
permitted to increase the metastatic disease response to CHT from 31% to 97% of to CHT. So far, the
overall survival rate of children with HB and metastases at diagnosis have been reported as 44–79% at
3 years and 27–57% at 5 years of follow up, while the EFS is 21–77% at 3-years and 21–28% at 5 years of
follow up [5,6,15–20].
Table 1. Response and outcomes of different chemotherapeutic protocols in hepatoblastoma with
distant metastases at diagnosis.
Response to CHT Protocols Outcomes
Study
n of
Metastatic
Patients
Non-Resected
at Diagnosis
(%)
Responders to
Neoadjuvant
CHT (%)
Eligible for
Delayed Final
Resection (%)
Resectable after
Neoadjuvant
CHT (%)
EFS (%) OverallSurvival (%)
COG
(AHEP-0731) [5] 29 100 31 - 69 49 (3 years) 62 (3 years)
JPLT-2 [16] 35 100 43 - - 21 (5 years) 44 (5 years)
SIOPEL-4 [6] 39 67.6 97 88.7 95 77 (3 years) 79 (3 years)
SIOPEL-3 [17] 70 98.7 71 83 91 56 (3 years) 62 (3 years)
SIOPEL-2 [18] 25 - 72 60 - - 44 (3 years)
SIOPEL-1 [19] 31 - 84 - - 28 (5 years) 57 (5 years)
INT-0098 [20] 40 98.4 - 57.1 47 25 (5 years) 37 (5 years)
POG-9345 [21] 11 - - 36 - 27 (5 years) 27 (5 years)
Abbreviations: CHT: chemotherapy; EFS: event-free survival; JPLT, Japanese Study Group for Pediatric Liver Tumors;
n, number; POG, Pediatric Oncology Group; SIOPEL, International Childhood Liver Tumour Strategy Group.
Across different protocols, children with HB and lung metastasis at diagnosis are treated with
neoadjuvant CHT followed by surgical resection of the primary tumor +/− pulmonary metastases,
according to the primary tumor resectability and lung metastasis response to CHT [5,6,15–20].
Following the selection criteria described above, to the best of our knowledge we identified
434 patients affected by HB with synchronous lung metastases described in literature between 1990 and
2018. All children underwent neoadjuvant CHT before any surgical treatment and 43.5% of children
completely cleared lung metastases after neoadjuvant CHT. Primary tumour surgery was performed
in 407 (93.8%) of children and the surgical treatment consisted of liver resection in 183 (45%) of cases,
LT in 61 (15%) of cases, while in 162 (40%) of patients’ surgical details were not specified. Of 91 (21%)
of patients undergoing surgical resection of lung metastases, 25 (27.5%) had lung metastasectomy after
primary tumour surgery, 22 (24.2%) before (mainly for LT) and 14 (15.4%) simultaneous to primary
tumour surgery. After a median follow up of 4 years, the overall survival rate was 83% and recurrence
rate 40% (Table 2).
Table 2. Characteristics of patients affected by hepatoblastoma and synchronous lung metastases
reported in literature.
Hepatoblastoma (HB) and Synchronous Lung Metastasis Number (%, Range)
n of patients with HB and synchronous lung metastasis 434
n of patients with lung metastasis cleared after neoadjuvant CHT 189 (43.5%)
n of patients undergoing lung metastasectomy 91 (21%)
Timing of lung metastasectomy:
-Before primary tumor surgery 22 (24.2%)
-After primary tumor surgery 25 (27.5%)
-Simultaneous to primary tumor surgery 14 (15.4%)
-Not specified 30 (32.9%)
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Table 2. Cont.
Hepatoblastoma (HB) and Synchronous Lung Metastasis Number (%, Range)
Primary liver surgery:
-Yes 407 (93.8%)
-No 27 (6.2%)
Type of primary tumor surgery:
-Liver resection 183 (45%)
-LT 61 (15%)
-Not specified 163 (40%)
Median time to last follow up 4 (1–12)
Overall survival rate 83% (0–100%)
Overall recurrence rate 40% (0–100%)
Abbreviations: CHT, chemotherapy; HB, hepatoblastoma; LT, liver transplantation; n, number.
5.1. Resectable Primary Liver Tumor and Synchronous Lung Metastasis
For children with HB and synchronous lung metastases who present resectable primary liver
tumor (according to the POSTEXT staging) after neoadjuvant CHT, surgical treatment of the primary
tumor follows the recommendations defined for HB without pulmonary metastases, by resecting
the hepatic segments involved within the tumor [4]. However, the management of lung disease not
cleared by neoadjuvant CHT varies greatly in terms of surgical approach and timings and not universal
recommendation have been defined yet.
In 2007, Meyers et al. [17] reported the first results from the COG (INT–0098 protocol).
They described 9 of 38 children affected by pulmonary metastatic HB at diagnosis, who underwent
metastasectomy for initial pulmonary metastasis after neo-adjuvant CHT at varying points respect the
surgery of the primary tumor (2 before, 5 simultaneous, and 2 after liver resection). Of those, 8 (88.9%)
survived at long-term follow-up and 3 had a tumor relapse. From those results, the authors suggest
that the management of metastases present at diagnosis and persisting after neoadjuvant CHT should
be more aggressive—and lung metastasectomy should be strongly considered—providing the primary
liver tumour is under control.
In 2013, Zsiros et al. [6] reported the excellent results of SIOPEL–4, characterized by increased
dose of cisplatin in the neoadjuvant CHT. Compared to the older SIOPEL studies [18,22,23], the most
important progress from SIOPEL-4 was demonstrated in the sub-group of children with HB and
synchronous lung metastasis: out of 39 patients, 97% responded to neoadjuvant CHT (20 complete
responses, 18 partial responses, 1 had no evaluation of lung lesions), with a 3-year EFS of 77% (95%
CI 63–90) and 3-year survival of 79% (95% CI 66–92) [6]. Complete tumor primary resection was
achieved in 70% of cases. Surgical treatment of the primary liver lesion in metastatic HB included
liver resection for all patients, except for 7 children with unresectable HB who underwent LT after
pulmonary metastases were cleared (6 with CHT, 1 with metastasectomy). Nineteen of the 20 HB
metastatic patients with complete response in the lungs were in remission at the last evaluation, while
in 1 patient, lung lesions recurred. Of the 18 patients with lung metastasis with partial response,
after the primary tumor surgery, 7 children underwent metastasectomy (6 complete, 1 incomplete but
nonviable tumor), and of these 4 children had complete remission. Six patients had residual lesions in
the lung after the preoperative CHT but did not undergo pulmonary metastasectomy and achieved
complete remission with further CHT. In 2 cases, lung lesions remained unresectable, and in one child,
liver resection was performed without metastasectomy. In 1 patient, surgery was not attempted. In this
series, only 1 (5%) patient had lung relapse at 3-year follow-up, results that demonstrate the stability
of lung response achieved by the SIOPEL–4 CHT regimen. The SIOPEL–4 results emphasize that
increased cisplatin dose in neoadjuvant CHT provides improved outcomes in metastatic HB, while
metastasectomy remains the only curative option in patients whose lung lesions are not cleared by
CHT alone.
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In 2017, Hishiki et al. [16] reviewed the JPLT–2 prospective cohort study in order to clarify the
role of pulmonary metastasectomy in HB with lung metastasis at diagnosis. Out of 60 patients affected
by HB and synchronous lung metastases who underwent neoadjuvant CHT, 1 patient died from early
CHT-related toxicity, while 59 completed the preoperative CHT scheme. Twenty-six (43%) children
had a complete response to CHT, while in the other 33 with residual metastases, 14 underwent at least
one metastasectomy before (n = 2) and after (n = 12) liver surgery. Among those who underwent
metastasectomy, pulmonary nodules were completely removed from 11 children, whereas 3 had
incomplete resection. In the same study, the metastasectomy group registered promising survival
rate when considering EFS (45%) and overall survival (63.6%) at 3 years. Moreover, in children who
underwent lung resection and liver surgery, the 3-year EFS increased to 55.6%, while it was 36.9% in
patients who only experienced liver surgery. In this series, metastasectomy was restricted to cases
that were not eradicated by CHT. Whereas the rate of clearance of initial HB metastasis in the JPLT–2
trial was slightly lower compared to those reported in the SIOPLE–4 (43% versus 51%, respectively),
the authors state that intensifying CHT induction with the aim to control the lung disease, as in the
SIOPEL–4 protocol, appears to be a reasonable strategy for improving the survival of patients with
lung metastases. Consistent with the previous report from the same group, the JPLT–2 stated that
among children with HB with lung metastasis at diagnosis, the best outcomes are achieved by complete
response by CHT only, as expected. Yet, for cases that have residual disease after CHT, aggressive
pulmonary metastasectomy may improve their outcome, provided that the liver tumor has been, or is
expected to be, completely resected. Unfortunately, none of the abovementioned studies report on
eventual surgical complications after metastasis resection.
Based on previous trials, in the current PHITT, children with HB and synchronous lung metastasis
(high-risk group), after receiving initial 3 blocks of cisplatin-intensive SIOPEL–4 regimen, are stratified
in 2 risk groups: patients with lung complete response will undergo resection of the primary tumor
at any time after the completion of the induction therapy, followed by CHT consolidation; on the
other hand, patients with lung metastases not cleared at the end of CHT induction are randomized to
two different intensified consolidation therapies and surgical resection of the primary tumor can be
considered at any time after the induction therapy, thus lung metastasectomy might be considered in
all patients if continuing to respond to consolidation therapy [14].
5.2. Unresectable Primary Liver Tumor and Synchronous Lung Metastasis
Children with HB and metastatic disease at diagnosis, whose primary tumor remains unresectable
after neoadjuvant CHT (defined as multifocal HB involving all four liver sections, tumor located next
to both the main portal vessels, at the hilum of the liver or next to all three hepatic veins) are candidates
for LT only if the metastatic disease is cleared with chemotherapeutic regimens and/or with pulmonary
metastasectomy [13]. Unresponsive or progressive metastatic disease after neoadjuvant CHT is a
contraindication for LT, because even if the nodules can be surgically resected, microscopic foci of a
chemoresistant tumor are highly probable [24,25]. Therefore, lung metastases in patients who appear
to respond to CHT, but who do not entirely clear, might benefit from surgical metastasectomy to allow
subsequent LT [26,27].
In SIOPEL–4 [6], out of 7 children with HB and lung metastasis at diagnosis who underwent LT,
after they cleared pulmonary metastasis (6 with CHT, 1 with metastasectomy [no viable tumor cells
found in the specimen]), none had pulmonary relapse at 3-year follow-up. Based on these promising
results, the SIOPEL group emphasises that the presence of lung metastasis at diagnosis is not a
contraindication for LT, provided that effective preoperative CHT is provided and lung lesions respond
to treatment and are completely cleared before transplantation by CHT and/or metastasectomy. Recently,
Triana Junco et al. [1] also reported excellent LT outcomes for unresectable HB with synchronous lung
metastasis eradicated before transplantation (1-year survival: 93.3% ± 4.6%; 5-year survival: 86.4%
± 6.3%). This data demonstrated that the presence of metastasis at diagnosis (12.9% of the study
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population), if resolved before LT, was not a risk factor of tumour recurrence and did not influence
long-term survivals.
From our research, we found 61 children with HB and synchronous lung metastasis at diagnosis
undergoing LT: all patients received neoadjuvant CHT and in 39 (63.9%) cases lung metastases were
cleared by CHT alone before LT, while in 22 (36%) cases lung lesions resistant to CHT were resected
before LT.
Due to the high response of lung metastases to neoadjuvant CHT and optimal LT outcomes,
several trials recommend that intensification of the chemotherapeutic regimens that aim to completely
clear pulmonary lesions is needed, especially for children with unresectable primary tumors who may
benefit from transplantation [3,5,6].
A large series from the Surveillance, Epidemiology, and End Results (SEER) database reported
that outcomes of children with HB who underwent LT (for unresectable liver tumor) were similar to
these achieved in patients who underwent liver resection (for resectable liver tumor), with a 5-year
survival of 86.5% and 85.6%, respectively (hazards ratio (HR) = 0.58, 95% confidence interval (CI)
0.07–5.10) [13,28]. In the initial experience, primary LT for unresectable HB demonstrated much better
results (85%) than salvage LT (40%) after a 10-year follow-up [1,29]. Nevertheless, recent evidence
from the nationwide survey of the outcomes of liver donor liver transplantation (LDLT) in Japan [30]
showed similar results for rescue LT and primary LT: Sakamoto et al. reported that children (n= 15)
who received initial liver resection, followed by rescue LDLT, showed comparable outcomes compared
to patients (n= 24) treated by primary LDLT (recurrence free-survival rate at 1 and 3 years after LDLT
were 86.7% vs. 70.8% and 78% vs. 62.2%, respectively (p = 0.24)). These promising results are probably
related to the improving of JPLT chemotherapy protocols and need to be confirmed in other series.
Due to the limited organ availability and the fact that transplantation is not without morbidity and
mortality, authors suggest that liver resection should be careful considered on a case-by-case basis in
order to avoid LDLT for a patient who may have the chance to be cured by liver resection.
After LT, tumor relapse has been related to risk factors such as PRETEXT IV lesions, older age at
diagnosis, and longer waiting-list time. Consequently, several studies suggest that the liver transplant
surgical team should be involved in the management of children with HB from the early stages to
optimize outcomes, as also adopted in the PHITT [14,31]. To reduce the waiting-list time, from 2010
in the Pediatric End-Stage Liver Disease (PELD) allocation system, additional “exception” points are
assigned to children with HB in order prioritize them on the LT waiting list. In this context, the rapid
availability of organs from deceased donors (due to the prioritization of HB children on the waiting
list), as well as the increasing living-donor LT activity, play a key role in enhancing the survival rate [1].
Yet, in advanced HB with vascular involvement, the optimal treatment between extreme liver
resection and LT is still under debate. Indeed, each option has crucial drawbacks: non-conventional
liver resection with vascular reconstruction could expose the patient to tumor residual (R1) or to
major complications [32], while LT is associated with long-term immunosuppression side effects
(opportunistic infection, relapse or secondary neoplasm, transplant-related vascular and biliary
complications [33]). Therefore, in children with lung metastasis resistant to CHT (not candidate to LT)
and/or in countries where organ availability is limited, extreme liver resection should be considered on
case-by-case basis [30].
However, the optimal long-term outcomes of children who undergo LT at these stages suggest that
transplantation is paramount when associated with effective preoperative CHT, and it is increasingly
indicated when HB includes major venous invasion and multifocal PRETEXT IV, along with the absence
of metastatic disease [1].
5.3. Unresectable Primary Liver Tumor and Synchronous Lung Metastases Progressing during
Neoadjuvant Chemotherapy
In patients whose tumors progress or remain unresectable after neoadjuvant CHT as well as in
children who cannot undergo LT for residual lung metastases, interventional techniques (such as
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transarterial chemoembolization (TACE), high-intensity frequency ultrasound (HIFU), radiofrequency
ablation (RFA)) have been increasingly used. The aims of these techniques include decreasing tumor
progression, reducing tumor size in order to increase the feasibility of liver resection, and limiting
systemic CHT toxicity [34]. Unfortunately, the experiences of non-surgical treatment in patients with
HB and synchronous lung metastases are limited to a few cases, and the results focus on the local
tumor response and do not report outcomes of lung metastases.
Based on adult experience, preoperative TACE has been the most widely used approach in
paediatric HB, with the aim of reducing tumour volume (through providing intratumoral necrosis and
decreasing intraoperative bleeding) and allowing complete hepatic resection. However, the reported
cases in HB children are sparse, and the use of TACE followed by surgery does not always result
in a complete resection. Nevertheless, different series confirm that the presence of lung metastases
is associated to poor outcomes [35–37]. Li et al. [36] reported encouraging results of 12 children
with advanced HB treated by TACE, which permitted a mean tumor reduction of 69% (of the initial
volume) followed by primary tumour resection in 83% of cases, without significant TACE-related
toxicity. Interestingly, one child with unresectable HB and pulmonary metastases first received CHT
treatment, which cleared lung lesions, followed by TACE, which permitted a subsequent surgical
resection. However, long-term outcomes are not reported.
HIFU is a technique that allows focal delivery of high-intensity ultrasound beams directly
to the tumor to enhance cell death. In a controlled, non-randomized prospective trial, HIFU
combined with TACE was used for the treatment of unresectable HB with metastatic disease, and
outcomes were compared to those obtained in children treated only by neo-adjuvant CHT (cispltain–5
fluorouracil–vincristine) [34]. In this report, the combined HIFU–TACE treatment improved the rate
of radical resection and provided a higher and more rapid tumor size reduction within 6 months
compared to the CHT group, without major complications. From these results, the authors propose that
the combination of HIFU–TACE can be considered as upfront treatment for local control of advanced
HB, with the advantage of not increasing CHT drug resistance. The HIFU–TACE benefit could be
especially relevant in patients with metastatic disease. However, these promising results should be
confirmed by larger trials.
Yevich et al. recently reported that also RFA is a safe and effective reiterative therapeutic option
(either for the treatment of the primary liver tumor or lung metastasis) in children with metastatic HB,
whom surgical resection is clinically contraindicated [38]. Although stem cell transplantation has been
explored in patients with unresectable HB as an upfront treatment, it has not yet been proven beneficial
due to the risk of toxicity and lack of evident capacity of rending HB tumor resectable. Therefore, the
use of stem cell transplantation in metastatic HB requires further investigation [39–41].
The effectiveness of new anticancer agents, such as sorafenib and regorafenib, are currently
investigated and have been demonstrated to reduce tumor growth in HB cell lines in vitro [42,43].
To the best of our knowledge, in clinical setting the use of sorafenib, combined with CHT cisplatin-based,
is limited to case reports with recurrent metastatic HB after LT as second-line therapy [44,45], while
there are no clinical data regarding regorafenib in children with HB.
6. Surgical Lung Metastatectomy: When and How?
Due to the excellent response of the metastatic disease to CHT, all international trials recommend
the surgical treatment of lung lesions only in the cases of remnant pulmonary metastasis after
neoadjuvant CHT or pulmonary relapses [3,5,6,16]. Contraindications to metastasectomy include only
the inability to achieve a complete resection while preserving adequate lung function and the presence
of uncontrolled disease at the primary site [4]. Yet, the timing of lung metastasectomy (before, after, or
simultaneous to the surgical resection of the primary tumor) as well as the optimal surgical approach
to pulmonary metastasis is still under debate. To the best of our knowledge, a summary of all reports
available in literature describing the surgical approach of the primary liver tumor and the management
of lung metastasis in children with HB and synchronous pulmonary metastases is reported in Table 3.
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Table 3. Literature reports that describe the surgical management and outcomes for children with hepatoblastoma and synchronous lung metastasis.
Author Year
n of Patients with
HB and
Synchronous
Lung Metastases
Chemotherapy
(CHT) Protocol
n of Patients Who
Cleared Lung
Metastases with
Neoadjuvant CHT (%)
n of Patients with
Synchronous Lung
Metastases
Undergoing
Metastasectomy (%)
Timing of Lung
Metastasectomy Respect
the Primary Liver Surgery
(after/before/simultaneous)
Type of Primary
Liver Surgery
(Resection/LT)
Follow up OverallSurvival
Recurrence Rate
(%)
Langevin A [44] 1990 1 ADR + CDDP 100% - - Liver resection 2 years 100% 0 (0%)
Iwafuchi M [45] 1991 2 ADR + CDDP - 2 After liver surgery Liver resection 1–3 years 100% 0 (0%)
Al-Qabandi
W [46] 1999 3 SIOPEL 1–2 3 (100%) - - 3 LT 2 years 100% -
Dower NA [47] 2000 2 Cisplatin-based 1 (50%) 1 (50%) After liver surgery 1 LT,1 liver resection 2–3 years 100% 50%
Nishimura SI [48] 2002 2 DOX/CDDP 1 (50%) 1 (50%) After liver surgery 2 liver resection 6 years 100% 50%
Srinivasan P [49] 2002 1 PLADO 1 (100%) - - 1 LT 8 months 100% 100%
Fuchs J [50] 2002 7
CDDP/IFO/DOX–VP16/CARBO
(GCLPT study HB
94)
1 (14.3%) na na
1 liver resection,
6 no primary
tumor surgery
5 years 85.7% na
Matsunaga T [8] 2003 20 CDDP +THP–ADR 11 (55%) 3 (15%) After liver surgery
19 liver resection
(11 complete, 8
incomplete)
3 years 51.9% 40%
Dicken BBJ [51] 2004 13 Cisplatin-based(not specified) 7 (53.8%) - - 13 liver resection 5 years 56.5%
87.5% (7 initially
cleared by CHT)
Khan AS [52] 2006 1 PLADO 1 (100%) - - 1 LT 5 years 100% 100%
Meyers [17] 2007 38 COG INT–0098protocol 20 (52.6%) 9 (45%)
2 before/5 simultaneous/2
afterliver surgery na 6–12 years
88.8% (all
initial
metastasectomy)
34.2%
D’Antiga [53] 2007 1
SIOPEL
(type not
specified)
- - - - 5 years 0%
Persistent lung
metastasis after
CHT
Suh M [54] 2008 1 COG (C5V +doxorubicin) - 1 (100%) Before liver surgery 1 LT 2 years 0% 100%
Faraj W [55] 2008 2 SIOPEL 1–4 2 (50%) - - 2 LT 1–10 years 50% 50%
Kosola S [56] 2010 2 SIOPEL–1 2 (100%) 1 (50%) Before liver surgery 2 LT 11 years
50% (1 died
after 15
years
disease-free)
50%
Zsiros J [57] 2010 70 SIOPEL–3 36 (52.2%) 2 (2.9%) na 26 liver resection,5 LT 4.5 years 62% 44%
Latuz TB [58] 2010 3 COG protocol(AHEP0731) 1 (33.3%) 2 (66.7%) na 3 liver resection 5 years 100% 33.3%
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Author Year
n of Patients with
HB and
Synchronous
Lung Metastases
Chemotherapy
(CHT) Protocol
n of Patients Who
Cleared Lung
Metastases with
Neoadjuvant CHT (%)
n of Patients with
Synchronous Lung
Metastases
Undergoing
Metastasectomy (%)
Timing of Lung
Metastasectomy Respect
the Primary Liver Surgery
(after/before/simultaneous)
Type of Primary
Liver Surgery
(Resection/LT)
Follow up OverallSurvival
Recurrence Rate
(%)
Koh KN [59] 2011 16 2–cistplatin based(CCG–823F trial) na na na na 5 years 42.1 ± 12.8 % na
Hery G [60] 2011 2 SIOPEL 3–4 2 (100%) - - 2 LT 4.4/4.8 years 100% -
Ismail H [24] 2011 5 PLADO 2 (40%) - - 2 LT(3 unresectable) 3 years 50% 20% (after LT)
Cruz JR [61] 2013 8 Cisplatin-based(not specified) 6 (75%) 2 (25%) Before liver surgery 2 LT 5 years 85% 25%
Zsiros J [6] 2013 39 SIOPEL 4 25 (64.1%) 7 (17.9%) na 7 LTna liver resection 3 years 79% 5%
Wanaguru D [62] 2013 8 SIOPEL 5 (62.5%) - - 8 liver resection 2 years 100% 25%
Sakamoto S [30] 2014 3 JPLT–2 2 (66.7%) 1 (33.3%) Before liver surgery 3 LT 2–4 years 100% 33.3%
Zhang Y [63] 2014 12
AEP/ACP
protocols
(APBSCT
program)
- 7 (58.3%) na na 2 years 66.7% na
Pham TA [33] 2015 7 COG protocols(Cisplatin-based) na na na 7 LT 10 years 85.7% 28.6%
Urla C [64] 2015 7 na - 7 (100%) Simultaneous to liversurgery 7 liver resection 5 years 83% 28.6%
Samuk [65] 2016 2 na 1 (50%) 1 (50%) Before liver surgery 2 LT 1 year 50% 50%
Erginel B [66] 2016 2 na na 2 (100%) na na 3 years 50% -
Shanmugam N
[67] 2017 3 PLADO 3 (100%) - - 3 Liver resection 3 years 66% 33.3%
Hishiki T [16] 2017 60 JPLT–2 26 (43%) 14 (23.3%) 2 before/12 after liversurgery
2 LT
57 liver resection 3 years
63.6% for
lung
complete
resection;
41.8% for
lung tumor
not
incompletely
resected
37.3%
Fuchs J [68] 2017 9 SIOPEL or GPOH(not specified) 7 (77.8%) 2 (22.2%)
simultaneous to liver
surgery Liver resection 5 years 88% 11.1%
Busweiler et al.
[69] 2017 27 SIOPEL 1–4 na 7 (25.9%)
3 before/4 after liver
surgery
5 liver resection
2 LT 5 years na 22.2%
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Table 3. Cont.
Author Year
n of Patients with
HB and
Synchronous
Lung Metastases
Chemotherapy
(CHT) Protocol
n of Patients Who
Cleared Lung
Metastases with
Neoadjuvant CHT (%)
n of Patients with
Synchronous Lung
Metastases
Undergoing
Metastasectomy (%)
Timing of Lung
Metastasectomy Respect
the Primary Liver Surgery
(after/before/simultaneous)
Type of Primary
Liver Surgery
(Resection/LT)
Follow up OverallSurvival
Recurrence Rate
(%)
O’Neill A [5] 2017 29 COG protocol(AHEP0731) 10 (34.5%) 10 (34.5%) na
1 LT
19 liver resection
(9 not resected)
3 years 62% 44.8%
Khan AS [52] 2017 4 SIOPEL protocols 4 (100%) - - 4 LT 5 years 50% 50%
Isono [70] 2018 2 JPLT 1/2 1 (50%) 1 (50%) Before liver surgery 2 LT 5 years 100% 50%
Dall’Igna [71] 2018 4 SIOPEL 2–3 na na na na 5 years 75% 25%
Fonseca A [72] 2018 2 SuperPLADO/SIOPEL–4 2 (100%) - -
2 Liver resection
(extended-right
hepatectomy, 1
with vascular
reconstruction)
2.9–1.7 years 100% 50%
Ramos-Gonzalez
G [31] 2018 3 C5V - 3 (100%) Before liver surgery 3 LT 4 years 66.6% 30%
Uchida H [73] 2018 8 JPLT–2 4 (50%) 4 (50%) Before liver surgery 3 LT5 liver resection 2–5 years 100% 50%
Umeda K [74] 2018 3 ADR, CDDP,CBDCA 2 (66.7%) 1 (33.3%) Before liver surgery 3 LT 5 years 66.6% 66.7%
Abbreviations: AD, adriamycin; CHT, chemotherapy; C5V, cisplatin/5-flurouracil/vincristine; CBCDA, carboplatin; CDDP, Cis–Dichloro–Diamine–Platinum; COG, Children’s Oncology
Group; DOX, doxorubicin; EFS, event-free survival; JPLT, Japanese Study Group for Pediatric Liver Tumors; LT, liver transplantation n, number; SIOPEL, International Childhood Liver
Tumor Strategy Group.
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The AHEP0731 study results represent the largest prospective report that details the characteristics
and outcomes of children with metastatic HB [5]. Among 29 children with HB and lung metastasis
at diagnosis, 9 (31%) met Response Evaluation Criteria in Solid Tumor (RECIST) criteria (defined
as nodules ≥ 10 mm), 20 (69%) patients had bilateral disease and 9 (31%) patients had unilateral
disease. Ten (33%) underwent lung nodule metastasectomy after receiving CHT (median number of
metastases removed: 3 [range 1–12]), with no reported complications, and 2 of them did not receive
any additional CHT and remained alive with normal AFP levels. The overall 3-year EFS in patients
with lung metastasis was 49%, while the overall survival rate was 62%. In this series, the presence of
measurable disease by RECIST, the sum of nodule diameters greater than or equal to the cumulative
cohort median size (22 mm, with a range from 2 to 209 mm), bilateral pulmonary disease, and ≥ 10
nodules were associated with an increased risk of lower EFS. Since lesions that fail to meet RECIST
size criteria (< 10 mm) at diagnosis may contain viable tumor, whereas residual lesions at the end of
therapy may constitute eradicated tumor/scar tissue, the radiological criteria alone seem to not be the
optimal method for evaluating disease response and predicting the outcome in HB. The treatment
decision for metastatic HB should consider the presence of lesions at imaging evaluation as well as
the total nodule burden, change in size over time, lesion stability, and serum AFP levels. The authors
suggest that lesion biopsy at the end of therapy should be entertained for patients in whom serum AFP
levels fail to normalize and/or nodules fail to change or diminish significantly in size. Finally, the COG
experience emphasises that lung metastasectomy may be beneficial in patients whose lung disease did
not clear with CHT, especially to facilitate LT. Wanaguru et al. [62] also showed positive data, reporting
the outcomes of 8 HB patients with lung metastatic disease at diagnosis who underwent the SIOPEL
chemotherapeutic protocols and achieved an EFS of 62.5% and an overall survival of 100% after a
2-year follow up.
Most surgeons prefer to perform the pulmonary metastasectomy after the resection of the
primary tumor, because the control of primary HB is associated with improved outcomes [6,16,75].
The drawback of this staged approach is that adjuvant CHT may be delayed, and this consequence
may lead to a long time interval between pre- and post-operative CHT. Moreover, HB cells may
synthetize hepatocyte growth factor, the levels of which appear to increase after surgical resection with
subsequent stimulation of growth, invasion, motility, angiogenesis, and prolonged survival of the
tumour cells [76]. Based on this concept, Urla et al. [64] proposed the simultaneous resection of primary
liver tumour and lung metastasis as single-stage surgery. In this series, 7 children with metastatic HB
at diagnosis had all lung metastasis removed at the time of the liver surgery (number of metastasis
removed ranged from 1 to 8; in 3 cases, lung lesions were bilateral). Liver surgeries comprised 3
left-trisegmentectomy, 2 right-trisegmentectomy, 1 right hemihepatectomy with IVC reconstruction,
and 1 left-hemihepatectomy. At the 5-year follow up, a tumor recurred in 2 (28.6%) children, and
the overall survival rate was 83%. Additionally, Fuchs et al. reported the positive experience of 2
children with persistent lung lesions after neoadjuvant CHT who underwent lung metastasectomy
simultaneously with the primary tumor resection without increasing post-operative morbidity [68].
Alternatively, other authors prefer the pulmonary metastasectomy before liver resection to avoid
the effects of growth stimulation and tumour cell proliferation of metastasis triggered by hepatic
growth factors secreted after major liver surgery [77]. As detailed in Table 1, most of the experiences
of lung metastasectomy performed before surgical resection of the primary tumor were reported
for children candidates to LT, because post-operative immunosuppression can trigger the growth of
extrahepatic lesions.
The optimal surgical approach to pulmonary metastasectomy is still controversial, especially for
bilateral lung lesions, for which some authors prefer metachronous bilateral thoracotomies [75], while
others favor sternotomy [64]. Due to the lack of data on surgical complications after lung metastasectomy
in children with HB, there is no evidence as to the best approach for this issue. However, significant
experience on the surgical treatment of pulmonary metastasis from other paediatric solid tumors
shows that unilateral thoracotomy, bilateral thoracotomy, or median sternotomy are well tolerated in
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children [4]. Lung wedge resection is recommended (independent of the surgical approach) to provide
adequate residual lung function. In a series of 43 children who underwent lung resection for pulmonary
metastasis from solid tumor, Erginel et al. [66] demonstrated that non-anatomical wedge resection is
an ideal technique for pulmonary metastasectomy due to the preservation of lung parenchyma and
decreased blood loss. This procedure ensures a negative margin to avoid tumor recurrence (none of
the patients had local relapse). There is no clear limit to the number of metastases that can be resected;
thus, in the decision-strategy, the aim of each surgery is to achieve clear lungs [4,24].
For small lesions that are not palpable or are invisible, indocyanine green (ICG) navigation
surgery, using a fluorescence imaging system, is useful for HB lung metastasectomy [78]. ICG allows
detection of lesions as small as 0.062 mm in diameter that are located 5–10 mm from the surface, but
it is associated with 10–20% false positives. However, since lesions lying in deeper layers may go
undetected by ICG, intraoperative pathological analysis is still required to confirm negative surgical
margins. To improve ICG sensitivity, a novel overlay fluorescence imaging system, using real-time
navigation with an endoscope with the PINPOINT system, was recently proposed to achieve complete
resection, but further data are needed [79].
CT-guided localization followed by video-assisted thoracoscopic surgery is also proposed for the
metastasectomy of tiny pulmonary lesions (<5 mm). However, this technique may be associated with
complications, including pneumothorax, lung hemorrhage, and air embolism [80].
Due to the limited number of cases and the lack of long-term outcomes for children who undergo
pulmonary resection for synchronous lung metastases, it is not yet possible to provide recommendations
on the timing of resection of lung metastases that are resistant to CHT or the best surgical approach.
Nevertheless, the choice should be based on the tumor biology, resectability of the primary tumors and
the surgeon’s experience.
7. Conclusions and Future Perspectives
In recent years, there have been substantial improvements in HB treatment: from a few treatment
options, there is now a detailed risk-stratified tumor management plan that includes CHT and several
surgical approaches. While more children who face this illness now have better hopes to be cured,
attention should be focused on those patients who are diagnosed with a metastatic disease, where
the therapeutic decision-making can be difficult, because it is still not supported by evidence due to
the lack of data. In this scenario, the primary goal of the therapeutic management is to clear lung
metastasis and resect the primary tumor. Currently, the treatment of HB with synchronous metastases
requires a multi-modal approach of neoadjuvant CHT followed by surgery, and it strictly relies on the
PRETEXT and POSTTEXT stage of the tumor, its biology, and the efficacy of neoadjuvant CHT.
In most cases, lung metastases have a good response to neoadjuvant CHT. Children who completely
clear lung metastasis by CHT and undergo radical resection of the primary tumor have shown good
results with a 3-year patient survival of about 80%.
Contrarily, the inability to clear lung metastases at the end of the CHT treatment is one of the most
negative prognostic factors that greatly affects EFS and overall survival. Hence, in these children, every
effort should be made in order to ensure clearance of lung disease, both by intensification of CHT and/or
metastasectomy. If the primary tumor is resectable, lung lesions resistant to CHT might be surgical
resected before, after or simultaneously to the surgery of the liver tumor. Due to the limited number of
cases and the lack of long-term outcomes of children who undergo HB lung metastasectomy, it is not
yet possible to provide recommendations on the optimal timing of lung metastases resection and the
best surgical approach. Therefore, the choice should be based on the tumor biology, resectability of the
primary tumor, and the multidisciplinary team experience.
Children with HB and metastatic disease at diagnosis, whose primary tumor remains unresectable
after neoadjuvant CHT (multifocal HB involving all four liver sections; tumor located next to both the
main portal vessels, at the hilum of the liver or next to all three hepatic veins) are LT candidates only if
the metastatic disease is cleared and have been associated with excellent outcomes (5-year survival
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rate of up to 86%). Therefore, the aggressive management of lung metastases, either by intensification
of CHT and/or metastasectomy, is crucial given the high risk of tumour recurrence in the lungs caused
by the post-transplant immunosuppression.
In the presence of unresectable HB who cannot undergo LT for residual lung metastasis, alternative
loco-regional treatment (such as TACE, HIFU, or RFA) might be considered in order to reduce tumor
size and increase the feasibility of liver resection.
In children with HB and lung metastasis resistant to CHT, defining the viability of lung residual
lesions is of paramount importance in order to choose the surgical approach for the primary liver
tumor. So far, only resection and histological evaluation of the metastatic lesions allow clinicians to
define the extra-hepatic extension of the disease. However, the surgical resection of small, diffuse
metastatic lesions might be difficult to afford both by standard imaging and direct examination of the
lungs. To overcome this limitation, novel techniques, such as ICG fluoroscopy, appear to be useful
tools, but additional data are required to verify their utility.
In future prospective, due to the limited data available, more evidence from large-scale multicentre
clinical trials focused on children with HB and synchronous lung metastasis are needed to define a
tailored therapeutic management and to further improve outcomes.
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AFP Alpha-fetoprotein
CCG Children’s Cancer Group
CHIC Children’s Hepatic tumors International Collaboration
CHT Chemotherapy
COG Children’s Oncology Group
CT CT Computer Tomography
EFS Event-free Survival
GPOH German Society for Pediatric Oncology and Haematology
HB Hepatoblastoma
HIFU High-Intensity Frequency Ultrasound
ICG Indocyanine green
JPLT Japanese Study Group for Pediatric Liver Tumors
LDLT Living Donor Liver Transplantation
LT Liver Transplantation
PELD Pediatric End-Stage Liver Disease
PHITT Pediatric Hepatic International Malignancy Therapeutic Trial
PRISMA Preferred Reporting Items for Systemic Reviews and Meta-Analysis
PRETEXT Pre-Treatment Extent of Disease
POG Pediatric Oncology Group
POSTTEXT Post-Treatment Extent of Disease
RFA Radiofrequency Ablation
RECIST Response Evaluation Criteria in Solid Tumor
SIOPEL International Childhood Liver Tumour Strategy Group
TACE Transarterial Chemoembolization
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